NGM Biopharmaceuticals granted AstraZeneca's MedImmune an exclusive option to license worldwide rights to therapeutics for Type II diabetes identified using NGM's enteroendocrine cell (EEC) program

AstraZeneca plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

NGM Biopharmaceuticals Inc.

U.S. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced